224 related articles for article (PubMed ID: 23146058)
1. Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.
Walker A; Marcucci G
Expert Rev Hematol; 2012 Oct; 5(5):547-58. PubMed ID: 23146058
[TBL] [Abstract][Full Text] [Related]
2. Rethinking the gold standard for recurrent DNA mutations detection in acute myeloid leukemia.
Novaretti MC
Eur J Haematol; 2016 Feb; 96(2):109-10. PubMed ID: 26110968
[No Abstract] [Full Text] [Related]
3. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.
Alpermann T; Schnittger S; Eder C; Dicker F; Meggendorfer M; Kern W; Schmid C; Aul C; Staib P; Wendtner CM; Schmitz N; Haferlach C; Haferlach T
Haematologica; 2016 Feb; 101(2):e55-8. PubMed ID: 26471486
[No Abstract] [Full Text] [Related]
4. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?
Yang J; Schiffer CA
Expert Rev Hematol; 2012 Aug; 5(4):395-407. PubMed ID: 22992234
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia with normal cytogenetics.
Mawad R; Estey EH
Curr Oncol Rep; 2012 Oct; 14(5):359-68. PubMed ID: 22806102
[TBL] [Abstract][Full Text] [Related]
6. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia.
Wakita S; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Koizumi M; Fujiwara Y; Yui S; Fukunaga K; Ryotokuji T; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Fukuda T; Inokuchi K
Leukemia; 2016 Mar; 30(3):545-54. PubMed ID: 26488113
[TBL] [Abstract][Full Text] [Related]
7. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
[TBL] [Abstract][Full Text] [Related]
8. Genomics in acute myeloid leukemia: from identification to personalization.
Martin JM; Winer ES
R I Med J (2013); 2015 Nov; 98(11):27-30. PubMed ID: 26517252
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.
Marcucci G; Haferlach T; Döhner H
J Clin Oncol; 2011 Feb; 29(5):475-86. PubMed ID: 21220609
[TBL] [Abstract][Full Text] [Related]
10. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
11. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
12. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
13. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Falini B; Martelli MP
Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression in cytogenetically normal acute myeloid leukemia.
Marcucci G; Radmacher MD; Maharry K; Mrózek K; Ruppert AS; Paschka P; Vukosavljevic T; Whitman SP; Baldus CD; Langer C; Liu CG; Carroll AJ; Powell BL; Garzon R; Croce CM; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
N Engl J Med; 2008 May; 358(18):1919-28. PubMed ID: 18450603
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.
Alhumaid MS; Dasouki MJ; Ahmed SO; AbalKhail H; Hagos S; Wakil S; Hashmi SK
Acta Haematol; 2020; 143(6):583-593. PubMed ID: 32541138
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia.
Yamato G; Yamaguchi H; Handa H; Shiba N; Kawamura M; Wakita S; Inokuchi K; Hara Y; Ohki K; Okubo J; Park MJ; Sotomatsu M; Arakawa H; Hayashi Y
Genes Chromosomes Cancer; 2017 Nov; 56(11):800-809. PubMed ID: 28710806
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432
[TBL] [Abstract][Full Text] [Related]
18. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.
Cagnetta A; Adamia S; Acharya C; Patrone F; Miglino M; Nencioni A; Gobbi M; Cea M
Leuk Res; 2014 Jun; 38(6):649-59. PubMed ID: 24726781
[TBL] [Abstract][Full Text] [Related]
19. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
Goryainova NV
Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
[TBL] [Abstract][Full Text] [Related]
20. Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability?
Zebisch A; Hoefler G; Quehenberger F; Wölfler A; Sill H
Leukemia; 2013 Aug; 27(8):1777-8. PubMed ID: 23417030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
